Nanologica AB (publ)

Hi, Andreas Bhagwani, CEO and one of the largest owners of Nanorodica. I am here to comment on the report for the first quarter. In short, we have a very exciting project with a product called Enlabsiv, a non-silica product that we have now sold during this quarter. Super exciting. We have converted our distribution agreement in China. We have carried out a pre-trial submission. First, a little about the numbers. 5 million in sales, it is our highest product sales ever within Logica, which we are very proud of. A slightly lower result than expected, we have a decline of 4 million, which I will comment on a little closer very soon. For those of you who have studied the balance sheet, we know that we have a pre-selection rate that has increased by 4 million. The production works and we get the product out, so that's good. 23.5, a little over in liquid materials, then one should say that the performance emission The money has not yet reached the deadline. The production. For those of you who have read the report, you know that we have had some problems with the production again. We wanted to redo a setting. We had quite a low exchange rate in one process step. We made setting changes and received significantly lower exchange rates. That is, products that disappeared. And then we made a reduction of that. Since then, we have gone back to the original the settings that we had earlier. And it is also the case that this process step is not dependent, especially dependent on right now, so it does not stop production. A little bit about sales then, as you know, we have had products, we have started selling products and now we also have sales that came in in the quarter. We had a goal in 2024 to cover 100 million. We still think it is possible to cover 100 million, but rather on a yearly basis. We have two big customers, which we think will be a significant part of the turnover, but they have not yet started. And that is why we are making this adjustment in the goal from 100 million in 2024 to 100 million in the future. Bina then. We have made some changes. Super exciting market. We have a distributor called Yunbo that we have worked with for a long time. Already in 2019, they made a pre-payment and made a very large order, which made it possible to get started with the production. Since then, we have been working with the Chinese customers more and more intensively at the end here. And then we have noticed that they want to buy directly from us. And then the deal I have with Yunbo becomes more of a home school than something good. So we have made a change together with Jundbo. The analytical chromatography is still with the fashion company Alltech, Jundbo's fashion company. And we take preparatory chromatography ourselves. So we adapt to the market and as they want to buy, we still have a very good relationship with Alltech. They help us on some customer accounts, but we do it ourselves. It also has a very positive marginal effect, because we do not share it with Jundbo in the same way. So a very good development in China. Something about the customers and deliveries. I and Enlabsiv have talked about it before. A super exciting project. A pharmaceutical producer who came to us and wanted help with something that was not silica. We did a product development, made it a little smaller scale, then a little more in scale as a production partner. And now it was what we delivered. I met these customers last week. They are very pleased with the product we have delivered. This is a platform project, so they have several products, several of their pharmaceutical products that use this product, N-lapsid. And it's just more and more products that come in on this, so it's a very large volume over time that we're looking at, but as I said earlier, we don't really know when it will start. Will the next order come in three weeks or three months? We don't know, and that means that we have adjusted our income goal. We have for a long time had an insulin manufacturer in Asia that has developed our products. They continue to do so. I think they are at the end of the phase, but I don't really know. Same thing there, they have advertised for significant volumes already under 2024, but we don't know when they will start. Then we have other customers, not just these two, even though they are very important for how we see the future, especially the near future. And I would say that most of those who have come the longest are in China, and that is the GLP-1 to the boom, you can say, in China. China is the country where the first GLP-1 goes out of patent earlier, so there has been a very strong focus on GLP-1 development in China, and it really benefits us. And that was really all I wanted to say as a comment for the quarterly report for the first quarter. Thank you very much.